focus -WSS

focus

author：fashion 2025-10-02 21:36:22 - browse：4

You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for the last day here.

ASCO is more than half done. There is free coffee on the exhibit floor. One booth barista said their team had made 1,400 espressos in a day. Everyone’s perspective is alternating between two verses from Smashing Pumpkins, who are, lest you forget, a Chicago band. “Today is the greatest day I’ve ever known.” Also: “I’ll burn my eyes out before I get out.”

What if sometimes cancer doctors could give less medicine?

Are cancer drugs more likely to be cures? Or could they instead turn cancer into a chronic disease, in which medicines keep tumors in check but patients have to deal with their side effects, both physical and financial, for the rest of their lives.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： STAT Summit: How researchers deal with rejection

WSS

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Health care court cases: Humana, Sutter, Novant

STAT Summit: How researchers deal with rejection

Pharma companies must ensure equitable access to obesity drugs

Roche drug slashes death risk in early

explore

focus

What if sometimes cancer doctors could give less medicine?

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

How to save PrEP access — and even expand it

Teladoc has a new CEO, but challenges remain the same

23andMe had bad news about my health. I wish a person had delivered it

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Tori Bowie and the unacceptable rates of Black maternal death

STAT Virtual Event: ASCO Recap, Live!

23andMe had bad news about my health. I wish a person had delivered it

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Apple is now the first public company to be valued at $3 trillion

ADCs take center stage as promising cancer treatments

hotspot

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Moderna says combo Covid

Coercive sterilizations revealed by STAT prompt outrage

Report captures long Covid’s disabling effects and policy challenges

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

hotspot

Wikipedia

entertainment

Wikipedia